Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis

被引:21
作者
Akuta, N
Suzuki, F
Suzuki, Y
Sezaki, H
Hosaka, T
Someya, T
Kobayashi, M
Saitoh, S
Arase, Y
Ikeda, K
Kobayashi, M
Kumada, H
机构
[1] Toranomon Gen Hosp, Dept Gastroenterol, Minato Ku, Tokyo 1050001, Japan
[2] Toranomon Gen Hosp, Liver Res Lab, Tokyo 1050001, Japan
关键词
HCV; genotype; 2a; interferon monotherapy; hepatocyte steatosis; body mass index; ferritin; early viral kinetics; core; NS5A;
D O I
10.1002/jmv.20298
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The role of hepatocyte steatosis in interferon (IFN) resistance is still unclear, especially in patients infected with hepatitis C virus (HCV) genotype 2a. The present study was conducted in 364 consecutive non-cirrhotic naive patients infected with genotype 2a, who were evaluated for the severity of steatosis and response to IFN monotherapy after a 24-week median duration of therapy. The patients were examined for factors associated with steatosis and treatment efficacy according to the grade of steatosis. Early viral kinetics was also evaluated in 64 patients for predictors of response to therapy. Nine IFN-resistant patients were assessed for the relationship between amino acid sequence of HCV core region/NS5A and severity of steatosis. Multivariate analysis identified two independent factors associated with steatosis; serum ferritin >= 200 mu g/l and body mass index >= 25.0 kg/m(2). The sustained virological response rate in patients with high-grade steatosis was significantly lower than in the low-grade group. Study of early viral kinetics showed a significantly lower cumulative HCV-RNA negative rate for the high-grade than low-grade steatosis group. Sequence analysis of HCV core region/NS5A in IFN-resistant patients with or without steatosis failed to identify steatosis-specific amino acid substitutions associated with resistance. This study of HCV genotype 2a suggested that steatosis is associated with excess iron storage, and that it is an important predictor of efficacy of IFN monotherapy. Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis.
引用
收藏
页码:550 / 558
页数:9
相关论文
共 43 条
[1]   Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy [J].
Akuta, N ;
Suzuki, F ;
Tsubota, A ;
Suzuki, Y ;
Hosaka, T ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (03) :376-383
[2]   Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors [J].
Akuta, N ;
Suzuki, F ;
Tsubota, A ;
Suzuki, Y ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :831-836
[3]   Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets [J].
Barba, G ;
Harper, F ;
Harada, T ;
Kohara, M ;
Goulinet, S ;
Matsuura, Y ;
Eder, G ;
Schaff, Z ;
Chapman, MJ ;
Miyamura, T ;
Brechot, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1200-1205
[4]   Effect of combined interferon-α induction therapy and ribavirin on chronic hepatitis C virus infection:: a randomized multicentre study [J].
Bjoro, K ;
Bell, H ;
Hellum, KB ;
Skaug, K ;
Raknerud, N ;
Sandvei, P ;
Doskeland, B ;
Mæland, A ;
Lund-Tonnesen, S ;
Myrvang, B .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (02) :226-232
[5]   High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].
Bressler, BL ;
Guindi, M ;
Tomlinson, G ;
Heathcote, J .
HEPATOLOGY, 2003, 38 (03) :639-644
[6]   Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C:: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis [J].
Castéra, L ;
Hézode, C ;
Roudot-Thoraval, F ;
Lonjon, I ;
Zafrani, ES ;
Pawlotsky, JM ;
Dhumeaux, D .
GUT, 2004, 53 (03) :420-424
[7]   GENOTYPIC SUBTYPING OF HEPATITIS-C VIRUS [J].
CHAYAMA, K ;
TSUBOTA, A ;
ARASE, Y ;
SAITOH, S ;
KOIDA, I ;
IKEDA, K ;
MATSUMOTO, T ;
KOBAYASHI, M ;
IWASAKI, S ;
KOYAMA, S ;
MORINAGA, T ;
KUMADA, H .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1993, 8 (02) :150-156
[8]   Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection [J].
Chayama, K ;
Tsubota, A ;
Kobayashi, M ;
Okamoto, K ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Suzuki, Y ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1997, 25 (03) :745-749
[9]   Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation [J].
Clouston, AD ;
Jonsson, JR ;
Purdie, DM ;
Macdonald, GA ;
Pandeya, N ;
Shorthouse, C ;
Powell, EE .
JOURNAL OF HEPATOLOGY, 2001, 34 (02) :314-320
[10]   Host- and disease-specific factors affecting steatosis in chronic hepatitis C [J].
Czaja, AJ ;
Carpenter, HA ;
Santrach, PJ ;
Moore, SB .
JOURNAL OF HEPATOLOGY, 1998, 29 (02) :198-206